A detailed history of China Universal Asset Management Co., Ltd. transactions in Zai Lab LTD stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 9,559 shares of ZLAB stock, worth $252,644. This represents 0.03% of its overall portfolio holdings.

Number of Shares
9,559
Previous 6,045 58.13%
Holding current value
$252,644
Previous $104,000 121.15%
% of portfolio
0.03%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$16.25 - $24.14 $57,102 - $84,827
3,514 Added 58.13%
9,559 $230,000
Q2 2024

Jul 19, 2024

SELL
$13.72 - $21.55 $47,814 - $75,101
-3,485 Reduced 36.57%
6,045 $104,000
Q1 2024

Apr 29, 2024

BUY
$15.95 - $26.8 $59,461 - $99,910
3,728 Added 64.25%
9,530 $153,000
Q4 2023

May 21, 2024

SELL
$22.97 - $30.58 $85,632 - $114,002
-3,728 Reduced 39.12%
5,802 $158,000
Q4 2023

Jan 23, 2024

BUY
$22.97 - $30.58 $101,780 - $135,499
4,431 Added 323.19%
5,802 $159,000
Q3 2023

May 21, 2024

BUY
$22.72 - $31.49 $12,655 - $17,539
557 Added 68.43%
1,371 $33,000
Q3 2023

Oct 30, 2023

BUY
$22.72 - $31.49 $12,655 - $17,539
557 Added 68.43%
1,371 $33,000
Q2 2023

May 21, 2024

SELL
$25.3 - $39.67 $3,314 - $5,196
-131 Reduced 13.86%
814 $22,000
Q2 2023

Jul 27, 2023

SELL
$25.3 - $39.67 $3,314 - $5,196
-131 Reduced 13.86%
814 $23,000
Q1 2023

May 21, 2024

BUY
$30.21 - $48.1 $7,371 - $11,736
244 Added 34.81%
945 $31,000
Q1 2023

Apr 27, 2023

BUY
$30.21 - $48.1 $7,371 - $11,736
244 Added 34.81%
945 $31,000
Q4 2022

May 21, 2024

SELL
$22.28 - $38.71 $196,710 - $341,770
-8,829 Reduced 92.64%
701 $21,000
Q4 2022

Jan 31, 2023

BUY
$22.28 - $38.71 $1,136 - $1,974
51 Added 7.85%
701 $22,000
Q3 2022

Oct 21, 2022

BUY
$34.2 - $51.69 $22,230 - $33,598
650 New
650 $22,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.59B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.